Synapse - Gopakumar Iyer

Search Within

Gopakumar Vasudeva Iyer

Results (342)

A Multicenter, open-label phase 1/2 study of TYRA 300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 gene alterations (SURF301)

Meeting Abstract

Zhang, A.; Boni, V.; Hanson, A.; Mantia, C.; Weickhardt, A.; Yu, E.; Gupta, S.; Robert, M.; Iyer, G.; Millward, M.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma

Review

Zhang, T.; Tan, A.; Shah, A. Y.; Iyer, G.; Morris, V.; Michaud, S.; Sridhar, S. S.
The Oncologist (2024)

Fulltext@MSK | Save

DNA damage response alterations predict for neoadjuvant chemotherapy sensitivity in muscle-invasive bladder cancer: A correlative analysis of the SWOG S1314 trial

Journal Article

Iyer, G.; Tangen, C. M.; Sarfaty, M.; Regazzi, A. M.; Lee, I. L.; Fong, M.; Choi, W.; Dinney, C. P. N.; Flaig, T. W.; Thompson, I. M. Jr; more...
JCO Precision Oncology (2024)

Fulltext@MSK | Save

Genomic and clinical characterization of non-invasive papillary urothelial carcinoma

Meeting Abstract

Gurbuz, B. C.; Caraballo, B.; Tallman, J.; Koll, F.; Basar, M.; Chen, J. F.; Sarungbam, J.; Sirintrapun, S. J.; Chen, Y. B.; Gopalan, A.; more...
Laboratory Investigation (2024)

Fulltext@MSK | Save

Spatial profiling of urothelial carcinoma with aberrant histology identified significant intratumoral molecular and immune heterogeneity with clinical implications

Meeting Abstract

Kuo, F.; Basar, M.; Koll, F.; Chen, J. F.; Sarungbam, J.; Sirintrapun, S. J.; Chen, Y. B.; Gopalan, A.; Fine, S.; Tickoo, S.; more...
Laboratory Investigation (2024)

Fulltext@MSK | Save

Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001)

Meeting Abstract

Galsky, M. D.; Grande, E.; Necchi, A.; Koontz, M. Z.; Iyer, G.; Campbell, M. T.; Drakaki, A.; Loriot, Y.; Sokolowski, K. M.; Zhang, W.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma

Meeting Abstract

Iyer, G.; Gao, X.; Rasco, D. W.; Milowsky, M. I.; Garmezy, B.; Rivera, I. I. R.; Tepper, J.; Moles, M. A.; Gjini, E.; Bowden, M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

PRECISION 1: A phase 2, multicenter, open-label basket trial of <i>nab</i>-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2

Meeting Abstract

Iyer, G.; Kwiatkowski, D. J.; Ding, L.; Schmid, A. N.; Navarro, W. H.; Ahnert, J. R.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study

Meeting Abstract

Van der Heijden, M. S.; Powles, T.; Gupta, S.; Bedke, J.; Kikuchi, E.; De Wit, R.; Galsky, M. D.; Duran, I.; Necchi, A.; Retz, M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Analysis of inactivating TSC1 and TSC2 alterations in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database

Meeting Abstract

Iyer, G.; Palma, N. A.; Navarro, W. H.; Kwiatkowski, D. J.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save